Digestive Diseases and Sciences

, Volume 64, Issue 10, pp 2878–2892 | Cite as

Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma

  • Bin Yu
  • Youming DingEmail author
  • Xiaofeng Liao
  • Changhua Wang
  • Bin Wang
  • Xiaoyan Chen
Original Article



PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.


To investigate the expression profile of PARPBP and its role in hepatocellular carcinoma (HCC).


Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test. The prognostic value of PARPBP in HCC was evaluated by Kaplan–Meier method, Cox regression analysis, and nomogram. Gene set enrichment analysis (GSEA) was used to screen biological pathways correlated with PARPBP expression in HCC.


PARPBP was significantly upregulated in HCC tissues compared with normal liver tissues (P < 0.05). High PARPBP expression was significantly associated with elevated serum AFP level, vascular invasion, poor tumor differentiation, and advanced TNM stage (all P < 0.05). Kaplan–Meier analyses suggested that upregulation of PARPBP was correlated with worse overall survival (OS) and recurrence-free survival (RFS) in HCC. Multivariate analyses further confirmed that PARPBP upregulation was an independent indicator of poor OS and RFS (all P < 0.05). The prognostic nomograms based on PARPBP mRNA expression and TNM stage were superior to those based on the TNM staging system alone (all P < 0.05). Besides, PARPBP DNA copy gain and miR-139-5p downregulation were associated with PARPBP upregulation in HCC. GSEA revealed that “cell cycle,” “HR,” “DNA replication,” and “p53 signaling” pathways were enriched in high PARPBP expression group.


PARPBP may be a promising prognostic biomarker and candidate therapeutic target in HCC.


Hepatocellular carcinoma PARPBP PARI Prognosis 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefGoogle Scholar
  2. 2.
    Rich NE, Yopp AC, Singal AG. Medical management of hepatocellular carcinoma. J Oncol Pract. 2017;13:356–364.CrossRefGoogle Scholar
  3. 3.
    Su C. Survivin in survival of hepatocellular carcinoma. Cancer Lett. 2016;379:184–190.CrossRefGoogle Scholar
  4. 4.
    O’Connor KW, Dejsuphong D, Park E, et al. PARI overexpression promotes genomic instability and pancreatic tumorigenesis. Cancer Res. 2013;73:2529–2539.CrossRefGoogle Scholar
  5. 5.
    Moldovan GL, Dejsuphong D, Petalcorin MI, et al. Inhibition of homologous recombination by the PCNA-interacting protein PARI. Mol Cell. 2012;45:75–86.CrossRefGoogle Scholar
  6. 6.
    Piao L, Nakagawa H, Ueda K, et al. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage. Genes Chromosom Cancer. 2011;50:13–24.CrossRefGoogle Scholar
  7. 7.
    Jinawath N, Chamgramol Y, Furukawa Y, et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology. 2006;44:1025–1038.CrossRefGoogle Scholar
  8. 8.
    Tamura K, Furihata M, Tsunoda T, et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007;67:5117–5125.CrossRefGoogle Scholar
  9. 9.
    Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol. 2006;29:567–575.Google Scholar
  10. 10.
    van Dam S, Cordeiro R, Craig T, et al. GeneFriends: an online co-expression analysis tool to identify novel gene targets for aging and complex diseases. BMC Genomics. 2012;13:535.CrossRefGoogle Scholar
  11. 11.
    Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucl Acids Res. 2017;45:W98–W102.CrossRefGoogle Scholar
  12. 12.
    Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404.CrossRefGoogle Scholar
  13. 13.
    Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28:1248–1250.CrossRefGoogle Scholar
  14. 14.
    Paraskevopoulou MD, Georgakilas G, Kostoulas N, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucl Acids Res. 2013;41:W169–W173.CrossRefGoogle Scholar
  15. 15.
    Sticht C, De La Torre C, Parveen A, et al. miRWalk: an online resource for prediction of microRNA binding sites. PLoS ONE. 2018;13:e0206239.CrossRefGoogle Scholar
  16. 16.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–7259.CrossRefGoogle Scholar
  17. 17.
    Northen A, Asendorf T, Walson PD, et al. Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. Clin Biochem. 2018;52:20–25.CrossRefGoogle Scholar
  18. 18.
    Hou SC, Xiao MB, Ni RZ, et al. Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma. Oncol Lett. 2013;6:1152–1158.CrossRefGoogle Scholar
  19. 19.
    Ma J, Gao M, Lu Y, et al. Gain of 1q25-32, 12q23-24.3, and 17q12-22 facilitates tumorigenesis and progression of human squamous cell lung cancer. J Pathol. 2006;210:205–213.CrossRefGoogle Scholar
  20. 20.
    Poniah P, Mohd Zain S, Abdul Razack AH, et al. Genome-wide copy number analysis reveals candidate gene loci that confer susceptibility to high-grade prostate cancer. Urol Oncol. 2017;35:545e1–545e11.CrossRefGoogle Scholar
  21. 21.
    Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455.CrossRefGoogle Scholar
  22. 22.
    Catela Ivkovic T, Voss G, Cornella H, et al. microRNAs as cancer therapeutics: a step closer to clinical application. Cancer Lett. 2017;407:113–122.CrossRefGoogle Scholar
  23. 23.
    Wong CC, Wong CM, Tung EK, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140:322–331.CrossRefGoogle Scholar
  24. 24.
    Hua S, Lei L, Deng L, et al. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene. 2018;37:1624–1636.CrossRefGoogle Scholar
  25. 25.
    Chen J, Yu Y, Chen X, et al. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma. Cell Prolif. 2018;51:e12510.CrossRefGoogle Scholar
  26. 26.
    Agosta C, Laugier J, Guyon L, et al. MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer. Int J Cancer. 2018;143:944–957.CrossRefGoogle Scholar
  27. 27.
    Liu J, Li C, Jiang Y, et al. Tumor-suppressor role of miR-139-5p in endometrial cancer. Cancer Cell Int. 2018;18:51.CrossRefGoogle Scholar
  28. 28.
    Krstic J, Galhuber M, Schulz TJ, et al. p53 as a dichotomous regulator of liver disease: the dose makes the medicine. Int J Mol Sci. 2018;19:921.CrossRefGoogle Scholar
  29. 29.
    Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149.CrossRefGoogle Scholar
  30. 30.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.CrossRefGoogle Scholar
  31. 31.
    Burkovics P, Dome L, Juhasz S, et al. The PCNA-associated protein PARI negatively regulates homologous recombination via the inhibition of DNA repair synthesis. Nucl Acids Res. 2016;44:3176–3189.CrossRefGoogle Scholar
  32. 32.
    Errico A, Deshmukh K, Tanaka Y, et al. Identification of substrates for cyclin dependent kinases. Adv Enzyme Regul. 2010;50:375–399.CrossRefGoogle Scholar
  33. 33.
    Baugh EH, Ke H, Levine AJ, et al. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25:154–160.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Bin Yu
    • 1
  • Youming Ding
    • 1
    Email author
  • Xiaofeng Liao
    • 2
  • Changhua Wang
    • 3
  • Bin Wang
    • 1
  • Xiaoyan Chen
    • 1
  1. 1.Department of Hepatobiliary and Laparoscopic SurgeryRenmin Hospital of Wuhan UniversityWuhanPeople’s Republic of China
  2. 2.Department of General SurgeryXiangyang Central HospitalXiangyangPeople’s Republic of China
  3. 3.Department of Pathology and PathophysiologyWuhan University School of Basic Medical SciencesWuhanPeople’s Republic of China

Personalised recommendations